Authors
Latest:
Evidence-Based Intervention Reduces C. diff Rates in Adults With CancerSMUCLA implements high-touch wipe down intervention to address the need for environmental disinfection of cancer patient care areas.
Latest:
Pharmacomicrobiomic Study Shows Significant Gut Bacteria Role in Drug Metabolism and ExposureA recent study provides what may be the first in-depth examination of the molecular mechanism of biotransformation of a large number of orally administered agents by the human gut microbiota.
Latest:
Salt, Ticks, and Lyme: A Case of Lyme Neuroborreliosis Presenting as SIADHThis case report is the fourth documented case of Lyme-induced syndrome of inappro­priate secretion of antidiuretic hormone (SIADH).
Latest:
COVID-19 or the Flu? Identifying Similarities and DifferencesKey signs and symptoms to help distinguish between the 2 respiratory illnesses.
Latest:
The Parallels Between Congenital Rubella Syndrome & Congenital Zika InfectionResearch presented at the 2017 Annual Pediatric Academic Societies (PAS) meeting examines the similarities between Congenital Rubella Syndrome and Congenital Zika Infection.
Latest:
Hospital-Acquired and Ventilator-Associated Pneumonia: Highlights and Pitfalls of the 2016 IDSA / ATS GuidelinesHospital-acquired and ventilator-associated pneumonia account for 22% of all hospital-acquired infections.
Latest:
Multidrug-Resistant Pseudomonas aeruginosa Infections: Hard to Treat, But Hope on the Horizon?Two recently approved agents offer significant activity against these hard-to-treat conditions.
Latest:
Guidelines to Caring for Patients With Sepsis: Promise or Progress?Care continues to improve; however, drug-resistant pathogens and a lack of new agents to treat these infections remain a constant challenge.
Latest:
Changes in Therapy Recommendations in the 2019 ATS/IDSA Guidelines for Community-Acquired PneumoniaThis article highlights some key updates to the antimicrobial therapy recommendations in the updated community-acquired pneumonia guidelines.
Latest:
Hepatitis C and the Dwindling of Research FundingHepatitis C virus is the world’s most prevalent blood-borne viral infection for which a vaccine does not exist. To eliminate HCV infection on a global scale, experts argue that vaccine development needs to become a public health priority.
Latest:
Is Eravacycline Ready for Prime Time Against CRAB Pneumonia?Eravacycline is an antibiotic that has been touted for possible treatment of difficult-to-treat resistant (DTR) Gram-negative infections. But can it tackle carbapenem-resistant Acinetobacter baumannii (CRAB) infections?
Latest:
The Search Continues for How to Best Treat Non—Carbapenemase-Producing CRE InfectionsInfections caused by non–carbapenemase-producing carbapenem-resistant Enterobacteriaceae present challenges in the treatment paradigm. Given the limited clinical data, the preferred therapeutic approach remains unknown.
Latest:
Cryptosporidium: A Potentially Fatal Cause of Diarrhea in a Heart Transplant RecipientExpanding the differential for diarrhea beyond Clostridium difficile.
Latest:
Antibiotic Marketing and Pipeline Shortages in the Era of Stewardship: An Industry PerspectiveExploring the antibiotic commercial conundrum. ​
Latest:
Examining the Surprisingly High Impact of Viruses on CAP and the Utility of Procalcitonin in Treatment DecisionsThe impact of viruses on community-acquired pneumonia seems to be greater than initially realized and the use of procalcitonin may help distinguish infection type for appropriate treatment.
Latest:
Ibalizumab Effective for Multidrug-Resistant HIV-1 InfectionThis orphan drug is for patients with limited antiretroviral treatment options.
Latest:
New Study Provides Hope for Chronic Lyme Disease SufferersPatients with Lyme disease know that their symptoms and the effects of the disease can be debilitating and last for a long time, often persisting even after treatment.
Latest:
UNC Study Finds Some HIV Patients with Low Viral Loads Forgo TreatmentA recent UNC study found that about one-third of HIV-positive patients with low viral loads chose to ignore federal guidelines to begin ART.
Latest:
What's New from the CLSI Subcommittee on Antimicrobial Susceptibility Testing?In addition to other updates, new breakpoints have been added for cefiderocol and meropenem-vaborbactam.
Latest:
Double Trouble: Assessing the Impact of Combining Daptomycin and Fosfomycin for MRSA BacteremiaThis highlighted study looks at using these 2 therapies concurrently for this infection.
Latest:
SARS-CoV-2 Vaccine Shows Signs of Activity in Phase 1/2 StudyBNT162b1, a SARS-CoV-2 vaccine candidate, elicited promising early signs of immune activity in a placebo-controlled phase 1/2 study.
Latest:
New Initiatives for HIV Taking Off This YearAdvances in antiretroviral therapies increase opportunities for patients with HIV to have more successful treatment outcomes.
Latest:
Cognitive Disorders are a Risk Factor for Severe COVID-19Alzheimer’s disease, dementia, and genetic variations in areas key to viral infection are risk factors for severe COVID-19 a new study suggests.
Latest:
Cryptosporidium: A Potentially Fatal Cause of Diarrhea in a Heart Transplant RecipientExpanding the differential for diarrhea beyond Clostridium difficile.
Latest:
It Takes Two to TANGO With a CarbapenemaseBecause of the global rise in antimicrobial resistance, meropenem-vaborbactam, the first carbapenem/β-lactamase combina­tion medication, is a welcome new antibac­terial.
Latest:
Texas Could Be Site of Next Large Measles Outbreak, Study PredictsTexas could be the site of the next large measles outbreak in the United States, according to a new study that highlights the low vaccination rates among schools there.
